NO20084698L - Metode for fremstilling av indazolyl-ureaer som inhiberer vanilloidreseptor subtype 1(VR1) - Google Patents

Metode for fremstilling av indazolyl-ureaer som inhiberer vanilloidreseptor subtype 1(VR1)

Info

Publication number
NO20084698L
NO20084698L NO20084698A NO20084698A NO20084698L NO 20084698 L NO20084698 L NO 20084698L NO 20084698 A NO20084698 A NO 20084698A NO 20084698 A NO20084698 A NO 20084698A NO 20084698 L NO20084698 L NO 20084698L
Authority
NO
Norway
Prior art keywords
preparation
receptor subtype
vanilloid receptor
indazolyl
inhibit vanilloid
Prior art date
Application number
NO20084698A
Other languages
English (en)
Inventor
Kirill A Lukin
Margaret Chi-Ping Hsu
Dilinie P Fernando
Brian J Kotecki
Marvin R Leanna
Original Assignee
Abbvie Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbvie Inc filed Critical Abbvie Inc
Publication of NO20084698L publication Critical patent/NO20084698L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

Abstract

Den foreliggende oppfinnelsen angår en metode for fremstilling av indazolyl-ureaer som er nyttige som antagonister ovenfor vanilloidreseptor subtype 1 (VR1).
NO20084698A 2006-04-14 2008-11-07 Metode for fremstilling av indazolyl-ureaer som inhiberer vanilloidreseptor subtype 1(VR1) NO20084698L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US79209906P 2006-04-14 2006-04-14
PCT/US2007/066605 WO2007121339A2 (en) 2006-04-14 2007-04-13 Process for the preparation of indazolyl ureas that inhibit vanilloid subtype 1 (vr1) receptors

Publications (1)

Publication Number Publication Date
NO20084698L true NO20084698L (no) 2008-11-07

Family

ID=38610399

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20084698A NO20084698L (no) 2006-04-14 2008-11-07 Metode for fremstilling av indazolyl-ureaer som inhiberer vanilloidreseptor subtype 1(VR1)

Country Status (21)

Country Link
US (2) US7847104B2 (no)
EP (1) EP2012779B1 (no)
JP (1) JP2009533474A (no)
KR (2) KR20110017464A (no)
CN (4) CN102140081A (no)
AU (1) AU2007238019B2 (no)
BR (1) BRPI0709963A2 (no)
CA (1) CA2647261A1 (no)
CR (1) CR10357A (no)
EC (1) ECSP088878A (no)
ES (1) ES2385404T3 (no)
HK (1) HK1123725A1 (no)
MX (1) MX2008013205A (no)
MY (1) MY145334A (no)
NO (1) NO20084698L (no)
NZ (1) NZ571705A (no)
RU (1) RU2446161C2 (no)
TW (1) TW200815362A (no)
UA (1) UA94100C2 (no)
WO (1) WO2007121339A2 (no)
ZA (1) ZA200808596B (no)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2439705T3 (es) * 2007-10-25 2014-01-24 Genentech, Inc. Proceso para la preparación de compuestos de tienopirimidina
EP2489660A1 (en) * 2008-03-20 2012-08-22 Abbott Laboratories Methods for making central nervous system agents that are TRPV1 antagonists
CN102070420B (zh) * 2011-01-04 2013-12-18 常州大学 一种2-溴-6-氟苯甲醛的制备方法
US20140275505A1 (en) * 2013-03-13 2014-09-18 Dow Agrosciences Llc Process for the preparation of certain triaryl rhamnose carbamates
EP3484877B1 (de) 2016-07-12 2020-07-01 Bayer CropScience Aktiengesellschaft Bicyclische verbindungen als schädlingsbekämpfungsmittel
CN106977535A (zh) * 2017-04-28 2017-07-25 大连联化化学有限公司 一种合成2‑氰基3‑氟苯硼酸工艺

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1054833A (no) * 1963-08-09
DE2458965C3 (de) * 1974-12-13 1979-10-11 Bayer Ag, 5090 Leverkusen 3-Amino-indazol-N-carbonsäure-Derivate, Verfahren zu ihrer Herstellung sowie sie enthaltende Arzneimittel
DE69411176T2 (de) * 1993-08-20 1998-11-12 Smithkline Beecham Plc Amide und harnstoffderivate als 5ht1d rezeptor antagonisten
AU2002334217B2 (en) * 2001-10-26 2008-07-03 Aventis Pharmaceuticals Inc. Benzimidazoles and analogues and their use as protein kinases inhibitors
MXPA04008384A (es) 2002-04-26 2004-11-26 Upjohn Co Derivados de pirazina sustituidos.
CN1826324B (zh) * 2003-05-22 2011-12-07 雅培制药有限公司 吲唑、苯并异*唑和苯并异噻唑激酶抑制剂
US7375126B2 (en) * 2003-06-12 2008-05-20 Abbott Laboratories Fused compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor
US7015233B2 (en) * 2003-06-12 2006-03-21 Abbott Laboratories Fused compounds that inhibit vanilloid subtype 1 (VR1) receptor
KR20060110741A (ko) * 2003-06-30 2006-10-25 히프 바이오 인크 화합물, 조성물 및 방법
US20050267096A1 (en) * 2004-05-26 2005-12-01 Pfizer Inc New indazole and indolone derivatives and their use pharmaceuticals
WO2006020070A2 (en) * 2004-07-16 2006-02-23 Teva Pharmaceutical Industries, Ltd. Indanylamino uracils and their use as antioxidants and neuroprotectants
US20070021450A1 (en) * 2004-07-16 2007-01-25 Benjamin Sklarz Indanylamino uracils and their use as antioxidants and neuroprotectants
US8071609B2 (en) * 2005-08-11 2011-12-06 Ariad Pharmaceuticals, Inc. Unsaturated heterocyclic derivatives
GB0520657D0 (en) * 2005-10-11 2005-11-16 Ludwig Inst Cancer Res Pharmaceutical compounds
US20070161645A1 (en) * 2005-11-02 2007-07-12 Targegen, Inc. Thiazole inhibitors targeting resistant kinase mutations
EP1960355A1 (en) * 2005-11-30 2008-08-27 F.Hoffmann-La Roche Ag 3-amino-1-arylpropyl indoles and aza-substituted indoles

Also Published As

Publication number Publication date
CN102140081A (zh) 2011-08-03
JP2009533474A (ja) 2009-09-17
CN102321025A (zh) 2012-01-18
ZA200808596B (en) 2010-03-31
EP2012779B1 (en) 2012-05-16
RU2008144961A (ru) 2010-05-20
US7847104B2 (en) 2010-12-07
KR20110017464A (ko) 2011-02-21
AU2007238019A1 (en) 2007-10-25
AU2007238019B2 (en) 2013-03-14
MY145334A (en) 2012-01-31
CA2647261A1 (en) 2007-10-25
CN102775350A (zh) 2012-11-14
MX2008013205A (es) 2008-10-22
WO2007121339A3 (en) 2008-10-02
ES2385404T3 (es) 2012-07-24
US20070244178A1 (en) 2007-10-18
HK1123725A1 (en) 2009-06-26
BRPI0709963A2 (pt) 2011-08-02
US8519186B2 (en) 2013-08-27
EP2012779A2 (en) 2009-01-14
RU2446161C2 (ru) 2012-03-27
TW200815362A (en) 2008-04-01
UA94100C2 (ru) 2011-04-11
CN101466374A (zh) 2009-06-24
CR10357A (es) 2008-12-11
KR20090003335A (ko) 2009-01-09
KR101118932B1 (ko) 2012-02-27
US20110040102A1 (en) 2011-02-17
CN101466374B (zh) 2012-03-21
ECSP088878A (es) 2008-12-30
EP2012779A4 (en) 2010-11-24
NZ571705A (en) 2012-03-30
WO2007121339A2 (en) 2007-10-25

Similar Documents

Publication Publication Date Title
EA200700365A1 (ru) Производные индол-2-карбоксамидина как антагонисты nmda рецептора
ATE537170T1 (de) Cgrp-rezeptorantagonisten
ATE411323T1 (de) Cgrp-rezeptorantagonisten
DE602005027230D1 (de) Cgrp-rezeptorantagonisten
ZA201102735B (en) Antagonists of the vanilloid receptor subtype 1(vr1) and uses thereof
ATE463495T1 (de) Oxadiazolylpyrazolopyrimidine als mglur2- antagonisten
DE602005020655D1 (de) Carboxamid-spirolactam-cgrp-rezeptor-antagonisten
CY1109854T1 (el) Παραγωγα αζαδικυκλο(3.1.0)εξανιου χρησιμα ως ρυθμιστες υποδοχεων d3 ντοπαμινης
MX2009005462A (es) Analogos de 7,8-saturados-4,5-epoxi-morfinano.
ATE429427T1 (de) Pyrimidinderivate als orexin-rezeptorantagonisten
WO2006041830A3 (en) Cgrp receptor antagonists
TW200714587A (en) Biphenyl compounds useful as muscarinic receptor antagonists
DE602005027870D1 (de) Cgrp-rezeptorantagonisten
CY1108880T1 (el) Παραγωγα καρβοξαμιδιου ως ανταγωνιστες μουσκαρινικου υποδοχεα
NO20084698L (no) Metode for fremstilling av indazolyl-ureaer som inhiberer vanilloidreseptor subtype 1(VR1)
MX2010008713A (es) Derivados de 5,6-bisaril-2-piridina-carboxamida, su preparacion y su aplicacion en terapeutica como antagonistas de los receptores de la urotensina ii.
MX2007004661A (es) Derivados de 1-(hetero)aril-3-amino-pirrolidina para usarse como antagonistas del receptor mglur3.
EA200801549A1 (ru) Новые производные фенантридина в качестве антагонистов брадикинина
MY149973A (en) 3-carboxypropyl-aminotetralin derivatives as mu opioid receptor antagonists
ATE512142T1 (de) Pyrimidin- und chinazolinderivate als modulatoren der somatostatin-rezeptor aktivität
AR064306A1 (es) Antagonistas del receptor de angiotensina ii
EA200970189A1 (ru) Пирролидинонанилины как модуляторы прогестероновых рецепторов
ATE550324T1 (de) Neue nk1- und nk2-antagonisten
CY1106649T1 (el) Νεα 1-μεθοξυ-2-φαινυλ-αιθενια χρησιμα δια την παρασκευην 5-καρβοξαλδεϋδο-2,3-διϋδροβενζοξεπινων

Legal Events

Date Code Title Description
CHAD Change of the owner's name or address (par. 44 patent law, par. patentforskriften)

Owner name: ABBVIE INC., US

FC2A Withdrawal, rejection or dismissal of laid open patent application